Loading...
•
Dec 31, 2021
uniQure Q4 2021 Earnings Report
uniQure reported financial results for 2021 and highlighted recent progress across its business.
Key Takeaways
uniQure reported a strong financial year, ending with $556.3 million in cash and cash equivalents. The company's revenue significantly increased due to the CSL Behring transaction and milestone payments. Net income was $329.6 million, a substantial improvement compared to the previous year's loss.
Ended 2021 with $556.3 million in cash and cash equivalents.
Revenue for the year was $524.0 million, driven by the CSL Behring transaction.
Net income for the year was $329.6 million, a significant increase from the previous year.
Advanced clinical-stage programs and expanded the research pipeline.
uniQure
uniQure
Forward Guidance
uniQure is focused on maintaining momentum in enrolling Phase I/II studies in Huntington’s disease, sharing safety and biomarker data, advancing gene therapy product candidates for Fabry disease and refractory temporal lobe epilepsy, and expanding its manufacturing footprint.
Positive Outlook
- Maintaining strong momentum in enrolling Phase I/II studies in Huntington’s disease.
- Sharing additional safety and biomarker data from patients in the lower dose cohort.
- Advancing gene therapy product candidates for Fabry disease and refractory temporal lobe epilepsy into IND-enabling toxicology studies.
- Initiating at least two new gene therapy programs targeting the liver and CNS during the year.
- Expanding manufacturing footprint with a second cGMP facility in Amsterdam.
Challenges Ahead
- Risks associated with the impact of the ongoing COVID-19 pandemic.
- Risks related to clinical development activities.
- Risks related to clinical results.
- Risks related to regulatory oversight.
- Risks related to product commercialization and intellectual property claims.